- Current report filing (8-K)

Table of Contents

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

April 16, 2009

 

Date of Report (Date of earliest event reported)

OSI PHARMACEUTICALS, INC.

 

(Exact name of registrant as specified in its charter)

Delaware		0-15190		13-3159796
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

41 Pinelawn Road
Melville, NY 11747

 

(Address of principal executive offices)

[phone]

 

(Registrant’s telephone number, including area code)

N/A

 

(Former name or former address,
if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

---

TABLE OF CONTENTS

	ITEM 8.01. Other Events.
SIGNATURE

---

Table of Contents

ITEM 8.01. Other Events.

     On April 16, 2009, Roche, OSI Pharmaceuticals, Inc.’s collaborator for the distribution and sale of its oncology drug, Tarceva® (erlotinib), announced that global net sales for Tarceva for the quarter ended March 31, 2009 were approximately 320 million Swiss francs (or approximately $279 million on a U.S. dollar equivalent basis), which represents U.S. net sales of approximately $111 million and international net sales of approximately $168 million. The decline in U.S. net sales appears to be primarily related to the U.S. economic conditions.

-2-

---

Table of Contents

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 16, 2009	OSI PHARMACEUTICALS, INC.
	By:	/s/ Barbara A. Wood
		Barbara A. Wood
		Senior Vice President, General Counsel and Secretary

-3-